Adare Pharma Solutions Acquires Frontida BioPharm

Adare Pharma Solutions, a technology-driven CDMO , has acquired Frontida BioPharm, a vertically integrated CDMO focused on oral formulations. The acquisition expands Adare’s portfolio of offerings to include new capabilities such as high potency compound handling and packaging services.  The combination of the two organizations will further establish Adare as a leading development and manufacturing organization for complex dosage forms.

Together, the combined company will offer an expanded suite of services for complex oral formulations, such as taste masking, controlled release, high potency formulation manufacturing, and Bioavailability enhancement. The addition of Frontida brings Adare’s manufacturing footprint to seven sites globally and expands Adare’s integrated, end-to-end offering to its partners. The combined organization will be led by Vivek Sharma.
Vivek Sharma, Chief Executive Officer of Adare, said, “We are devoted to improving the quality of life for patients by solving the most complex formulation challenges for our customers, and we believe this acquisition will bolster our ability to achieve our mission. Frontida and Adare share a commitment to quality and innovation, and we are excited to continue growing together.  The combined company will Lead in the space of oral formulations, while expanding the services and technical offerings we provide to meet the needs of our customers and their patients.”
Dr. Song Li, Frontida’s Chairman added, “We are very excited about the opportunities this transaction is expected to provide to both existing and new clients. Our combined resources and capabilities will result in enhanced support and talent to ensure the success of their development and commercialization programs. This transaction is also a testament to the hard work, dedication, and caring culture of the team who has helped Frontida grow, enabling continued investment into the Philadelphia area, which is a respected home for pharmaceutical development and manufacturing. We look forward to continuing our work together to provide innovative, life-enhancing products to the US and global markets.”